Bulletin
Investor Alert

press release

May 3, 2022, 4:05 p.m. EDT

Caribou Biosciences to Present at Upcoming Investor Conference

BERKELEY, May 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. /zigman2/quotes/228313444/composite CRBU +7.29% , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:

  • BofA Securities 2022 Healthcare Conference Tuesday, May 10 [th] , at 8:00 am PT

A webcast of the fireside chat presentation will be accessible via Caribou's website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.

About Caribou's Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays" that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com .
"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc.
Contacts:
Amy Figueroa, CFA
Investor Relations and Corporate
Communications
afigueroa@cariboubio.com
Investors and Media:
Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhouselsa.com
swheeler@wheelhouselsa.com

COMTEX_406640353/2471/2022-05-03T16:05:29

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/228313444/composite
US : U.S.: Nasdaq
$ 10.75
+0.73 +7.29%
Volume: 3.38M
Aug. 16, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$609.62 million
Rev. per Employee
$135,273
loading...

Partner Center

Link to MarketWatch's Slice.